Products
Addressing important unmet medical needs
Our products
Camurus’ products are based on our proprietary FluidCrystal® technology and are designed to address important unmet medical needs.
Please visit Camurus’ global website to see the company’s products approved for use by regulatory agencies outside of the US.
Brixadi® (buprenorphine) extended-release for subcutaneous use
To learn more about Brixadi®, visit the website:
See US Prescribing Information including Boxed Warning
Brixadi is the US trademark for Camurus’ product Buvidal®. The product rights to Brixadi in North America are licensed to Braeburn Inc. by Camurus.